Update on the development of enterovirus 71 vaccines

Expert Opinion on Biological Therapy

Volumn 14, Issue 10, 2014, Pages 1455-1464

  Kung, Yu An ^a,b   Hung, Chuan Tien ^a,b   Liu, Yen Chin ^a,b   Shih, Shin Ru ^a,b,c  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Enterovirus 71; Inactivated EV71 whole virus vaccines; Recombinant VP1; Synthetic peptide; Virus like particle

Indexed keywords

ENTEROVIRUS 71 VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; INACTIVATED VACCINE; LIVE VACCINE; RECOMBINANT VACCINE;

ENTEROVIRUS 71; EPIDEMIC; GENOTYPE; HUMAN; IMMUNE RESPONSE; NONHUMAN; REVIEW; VACCINATION; ANIMAL; ENTEROVIRUS A; ENTEROVIRUS INFECTIONS; IMMUNOLOGY;

HUMAN ENTEROVIRUS 71;

ANIMALS; ENTEROVIRUS A, HUMAN; ENTEROVIRUS INFECTIONS; HUMANS; VACCINES, ATTENUATED; VACCINES, INACTIVATED; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 84907063541     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2014.935330     Document Type: Review

References (74)

1. Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 1974;129(3):304-9
2. van der Sand en S, Koopmans M, Uslu G, et al. Epidemiology of enterovirus 71 in the Netherlands, 1963 to 2008. J Clin Microbiol 2009;47(9):2826-33
3. Ooi MH, Wong SC, Lewthwaite P, et al. Clinical features, diagnosis, and management of enterovirus. Lancet Neurol 2010;9(11):1097-105
4. Koroleva GA, Lukashev AN, Khudiakova LV, et al. [Encephalomyelitis caused by enterovirus type 71 in children]. Vopr Virusol 2010;55(6):4-10
5. Whitton JL, Cornell CT, Feuer R. Host and virus determinants of picornavirus pathogenesis and tropism. Nat Rev Microbiol 2005;3(10):765-76
6. Yip CC, Lau SK, Woo PC, Yuen KY. Human enterovirus 71 epidemics: what's next? Emerg Health Threats J 2013;6:19780
7. Chua KB, Kasri AR. Hand foot and mouth disease due to enterovirus 71 in Malaysia. Virol Sin 2011;26(4):221-8
8. Shih SR,Ho MS,Lin KH,et al, Genetic analysis of enterovirus 71 isolated from fatal and non-fatal cases of hand, foot and mouth disease during an epidemic in Taiwan, 1998, Virus Res 2000, 68,(2):127-36.
9. Ho M, Chen ER, Hsu KH, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 1999;341(13):929-35
10. Wu Y, Yeo A, Phoon MC, et al. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis 2010;14(12):e1076-81
11. Chan KP, Goh KT, Chong CY, et al. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis 2003;9(1):78-85
12. Zeng M, El Khat ib NF, Tu S, et al. Seroepidemiology of Enterovirus 71 infection prior to the 2011 season in children in Shanghai. J Clin Virol 2012;53(4):285-9
13. Mirand A, Schuffenecker I, Henquell C, et al. Phylogenetic evidence for a recent spread of two populations of human enterovirus 71 in European countries. J Gen Virol 2010;91(Pt 9):2263-77
14. Witso E, Palacios G, Ronningen KS, et al. Asymptomatic circulation of HEV71 in Norway. Virus Res 2007;123(1):19-29
15. Bible JM, Iturriza-Gomara M, Megson B, et al. Molecular epidemiology of human enterovirus 71 in the United Kingdom from 1998 to 2006. J Clin Microbiol 2008;46(10):3192-200
16. Kapusinszky B, Szomor KN, Farkas A, et al. Detection of non-polio enteroviruses in Hungary 2000- 2008 and molecular epidemiology of enterovirus 71, coxsackievirus A16, and echovirus 30. Virus Genes 2010;40(2):163-73
17. Fowlkes AL, Honarmand S, Glaser C , et al. Enterovirus-associated encephalitis in the California encephalitis project, 1998- 2005. J Infect Dis 2008;198(11):1685-91
18. Sanders SA, Herrero LJ, McPhie K, et al. Molecular epidemiology of enterovirus 71 over two decades in an Australian urban community. Arch Virol 2006;151(5):1003-13
19. Siafakas N, Attilakos A, Vourli S, et al. Molecular detection and identification of enteroviruses in children admitted to a university hospital in Greece. Mol Cell Probes 2011;25(5 -6):249-54
20. Thoa le PK, Chiang PS, Khanh TH, et al. Genetic and antigenic characterization of enterovirus 71 in Ho Chi Minh City, Vietnam, 2011. PLoS One 2013;8(7):e69895
21. Seiff A. Cambodia unravels cause of mystery illness. Lancet 2012;380(9838):206
22. So lomon T, Lewthwaite P, Perera D, et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010;10(11):778-90
23. Nishimura Y, Shimojima M, Tano Y, et al. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med 2009;15(7):794-7
24. Yamayoshi S, Yamashita Y, Li J, et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 2009;15(7):798-801
25. Lin JY, Chen TC, Weng KF, et al. Viral and host proteins involved in picornavirus life cycle. J Biomed Sci 2009;16:103
26. Cardosa MJ, Perera D, Brown BA, et al. Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in the Asia-Pacific region: comparative analysis of the VP1 and VP4 genes. Emerg Infect Dis 2003;9(4):461-8
27. Lee MS, Tseng FC, Wang JR, et al. Challenges to licensure of enterovirus 71 vaccines. PLoS Negl Trop Dis 2012;6(8):e1737
28. Yip CC, Lau SK, Zhou B, et al. Emergence of enterovirus 71 " doublerecombinant" strains belonging to a novel genotype D originating from southern China: first evidence for combination of intratypic and intertypic recombination events in EV71. Arch Virol 2010;155(9):1413-24
29. Chan YF,Sam IC,AbuBakar S. Phylogenetic designation of enterovirus 71 genotypes and subgenotypes using complete genome sequences. Infect Genet Evol 2010, 10, 3, 404-12.
30. Wu WH, Kuo TC, Lin YT, et al. Molecular epidemiology of enterovirus 71 infection in the central region of Taiwan from 2002 to 2012. PLoS One 2013;8(12):e83711
31. Chia MY, Chiang PS, Chung WY, et al. Epidemiology of enterovirus 71 infections in Taiwan. Pediatr Neonatol 2013;Epub ahead of print
32. Minor PD. Polio eradication, cessation of vaccination and re-emergence of disease. Nat Rev Microbiol 2004;2(6):473-82
33. Bek EJ, Hussain KM, Phuektes P, et al. Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Vaccine 2011;29(29 -30):4829-38
34. Dong C, Liu L, Zhao H, et al. Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine 2011;29(37):6269-75
35. Ong KC, Devi S, Cardosa MJ, Wong KT. Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol 2010;84(1):661-5
36. Liang Z, Mao Q, Gao Q, et al. Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV 71) vaccines. Vaccine 2011;29(52):9668-74
37. Meng FY, Li JX, Li XL, et al. Tolerability and immunogenicity of an inactivated enterovirus 71 vaccine in Chinese healthy adults and children: an open label, phase 1 clinical trial. Hum Vaccin Immunother 2012;8(5):668-74
38. Zhu FC, Liang ZL, Li XL, et al. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomi sed, double-blind, placebo-controlled phase 2 clinical trial. Lancet 2013;381(9871):1037-45
39. Zhu FC, Meng FY, Li JX, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebocontrolled, phase 3 trial. Lancet 2013;381(9882):2024-32
40. Li YP, Liang ZL, Gao Q, et al. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine 2012;30(22):3295-303
41. Li YP, Liang ZL, Xia JL, et al. Immunogenicity, saf ety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, Randomized, double-blind, placebocontrolled Trial. J Infect Dis 2014;209(1):46-55
42. Zhu F, Xu W, Xia J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med 2014;370(9):818-28
43. Chang JY, Chang CP, Tsai HH , et al. Selection and characterization of vaccine strain for Enterovirus 71 vaccine development. Vaccine 2012;30(4):703-11
44. Cheng A, Fung CP, Liu CC, et al. A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine 2013;31(20):2471-6
45. Chou AH, Liu CC, Chang JY, et al. Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers. PLoS One 2013;8(11):e79783
46. W u CN, Lin YC, Fann C, et al. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 2001;20(5 -6):895-904
47. Meng T, Kolpe AB, Kiener TK, et al. Display of VP1 on the surface of baculovirus and its immunogenicity against heterologous human enterovirus 71 strains in mice. PLoS One 2011;6(7):e21757
48. Chiu CH, Chu C, He CC, Lin TY. Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect 2006;8(7):1671-8
49. Yu Z, Huang Z, Sao C, et al. Oral immunization of mice using Bifidobacterium longum expressing VP1 protein from enterovirus 71. Arch Virol 2013;158(5):1071-7.
50. Qiwen D, Yu Z, Zeng W. Recombinant bifidobacterium for preparing EV (Enterovirus) 71 vaccine as well as preparation method and application of recombinant bifidobacterium. CN102703369; 2012
51. Chen HF, Chang MH, Chiang BL, Jeng ST. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine 2006;24(15):2944-51
52. Chen HL, Huang JY, Chu TW, et al. Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine 2008;26(23):2882-9
53. Chen CM, Chen HL. Enterovirus type 71 protein and method for production. US2011179508; 2011
54. Foo DG, Alonso S, Phoon MC, et al. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res 2007;125(1):61-8
55. Foo DG, Alonso S, Chow VT, Poh CL. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies e licited by a synthetic peptide. Microbes Infect 2007;9(11):1299-306
56. Liu JN, Wang W, Duo JY, et al. Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine 2010;28(46):7444-51
57. Liu CC, Chou AH, Lien SP, et al. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine 2011;29(26):4362-72
58. Grgacic EV, Anderson DA. Virus-like particles: passport to immune recognition. Methods 2006;40(1):60-5
59. Liu F, Wu X, Li L, et al. Use of baculovirus expression system for generation of virus-like particles: successes and challenges. Protein Expr Purif 2013;90(2):104-16
60. Hu YC, Hsu JT, Huang JH, et al. Formation of enterovirus-like particle aggregates by recombinant baculoviruses co-expressing P1 and 3CD in insect cells. Biotechnol Lett 2003;25( 12):919-25
61. Chung YC, Huang JH, Lai CW, et al. Expression, purification and characterization of enterovirus-71 viruslike particles. World J Gastroenterol 2006;12(6):921-7
62. Hu YC, Lin SY. Method for preparing virus-like particle and recombinant baculovirus used therein. TW201339302; US2013252311; CN103320394; 2013
63. Chung YC, Ho MS, Wu JC, et al. Immunizatio n with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 2008;26(15):1855-62
64. Galloway DA, Enssle J. Baculovirus-based enterovirus 71 VLP as a vaccine. WO2013142809; 2013
65. Lin YL, Yu CI, Hu YC, et al. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 viruslike particles. Vaccine 2012;30(7):1305-12
66. Ku Z, Ye X, Huang X, et al. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre-and post-attachment steps. PLoS One 2013;8(2):e57601
67. Li HY, Han JF, Qin CF, Chen R. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine 2013;31(3 2):3281-7
68. Chen R, Li HY, Lv K, He YL. Preparation method and application of self-combined immunogenic enteroviruslike particles in yeast. CN102925476; 2013
69. Arita M, Nagata N, Iwata N, et al. An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol 2007;81(17):9386-95
70. Chou AH, Liu CC, Chang JY, et al. Immunological evaluation and comparison of different EV71 vaccine candidates. Clin Dev Immunol 2012;2012:831282
71. Roldao A, Mellado MC , Castilho LR, et al. Virus-like particles in vaccine development. Expert Rev Vaccines 2010;9(10):1149-76
72. Han JF,Cao RY,Deng YQ,et al, Antibody dependent enhancement infection of enterovirus 71 in vitro and in vivo, Virol J, 2011, 8, 106.
73. Huang PN, Lin JY, Locker N, et al. Far upstream element binding protein 1 binds the internal ribosomal entry site of enterovirus 71 and enhances viral translation and viral growth. Nucleic Acids Res 2011;39(22):9633-48
74. Wang X, Peng W, Ren J, et al. A sensoradaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol 2012;19(4):424-9